» Articles » PMID: 38353876

Targeting Pannexin-1 Channels: Addressing the 'Gap' in Chronic Pain

Overview
Journal CNS Drugs
Specialties Neurology
Pharmacology
Date 2024 Feb 14
PMID 38353876
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic pain complicates many diseases and is notoriously difficult to treat. In search of new therapeutic targets, pannexin-1 (Panx1) channels have sparked intense interest as a key mechanism involved in a variety of chronic pain conditions. Panx1 channels are transmembrane proteins that release ions and small molecules, such as adenosine triphosphate (ATP). They are expressed along important nodes of the pain pathway, modulating activity of diverse cell types implicated in the development and progression of chronic pain caused by injury or pathology. This review highlights advances that have unlocked the core structure and machinery controlling Panx1 function with a focus on understanding and treating chronic pain.

References
1.
Woolf C . Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2010; 152(3 Suppl):S2-S15. PMC: 3268359. DOI: 10.1016/j.pain.2010.09.030. View

2.
Gold M, Gebhart G . Nociceptor sensitization in pain pathogenesis. Nat Med. 2010; 16(11):1248-57. PMC: 5022111. DOI: 10.1038/nm.2235. View

3.
Shupler M, Kramer J, Cragg J, Jutzeler C, Whitehurst D . Pan-Canadian Estimates of Chronic Pain Prevalence From 2000 to 2014: A Repeated Cross-Sectional Survey Analysis. J Pain. 2018; 20(5):557-565. DOI: 10.1016/j.jpain.2018.10.010. View

4.
Yong R, Mullins P, Bhattacharyya N . Prevalence of chronic pain among adults in the United States. Pain. 2021; 163(2):e328-e332. DOI: 10.1097/j.pain.0000000000002291. View

5.
Goldberg D, McGee S . Pain as a global public health priority. BMC Public Health. 2011; 11:770. PMC: 3201926. DOI: 10.1186/1471-2458-11-770. View